The Bureau of Industry and Security (BIS) opened 2026 with its most aggressive run of export-control settlements in years, anchored by a $252.5 million penalty against Applied Materials — the second-largest civil penalty BIS has ever imposed. For research offices, the headline number matters less than the pattern underneath it: nearly every enforcement action BIS has publicized this year traces back to the same handful of avoidable failures — unlicensed reexports, missed deemed-export screening, and controlled items shipped to sanctioned or restricted destinations without the paperwork to match. This page walks through what BIS has actually confirmed, what it signals about enforcement priorities, and what it means for institutions managing EAR and ITAR compliance around research collaboration.
The headline case: Applied Materials’ $252.5 million settlement
On February 11, 2026, BIS announced a civil settlement with Applied Materials, Inc. and its Korean subsidiary, Applied Materials Korea, resolving allegations that the companies reexported controlled semiconductor manufacturing equipment to a restricted Chinese entity without the required Export Administration Regulations (EAR) authorization. The $252.5 million penalty represents the statutory maximum — twice the value of the underlying transactions — and trade-compliance counsel have described it as a record civil penalty for BIS, second only in size to the agency’s largest-ever settlement. Beyond the fine, the settlement required Applied Materials to complete two internal compliance audits with findings reported to BIS, and imposed a three-year denial of export privileges that is suspended contingent on timely payment of the penalty and completion of the audits.
BIS’s own enforcement page lists a run of other 2026 resolutions alongside Applied Materials, including settlements involving Robert Bosch GmbH (roughly $36 million, tied to shipments implicating Huawei), Teledyne FLIR, Solventum Corporation, Coastal PVA Technology, Exyte, and Vizicom ICT. BIS has not published full penalty detail for every one of these on the same page, so this piece does not attempt to state a dollar figure for each; the pattern that matters for research institutions is the volume and consistency of the enforcement activity, not any single number.
What the 2026 enforcement pattern signals
Trade-compliance commentary following the Applied Materials case has converged on a consistent read: BIS is treating semiconductor and advanced-computing supply chains, and reexports that route around China-related restrictions, as its top enforcement priority for the year. That doesn’t mean research institutions are off the radar — it means the largest dollar figures are currently concentrated in industry, while the underlying legal theory (unauthorized reexport of controlled items to a restricted or unlicensed destination) is exactly the same theory that has been applied to universities and research centers in prior cases.
The research-institution precedent: Indiana University’s Drosophila Stock Center
The clearest illustration of how this theory applies inside a research office isn’t from 2026 — it’s a 2024 BIS settlement that research administrators should still treat as the operative case study, because nothing about the underlying fact pattern has become less likely since. In June 2024, BIS settled with Indiana University over 42 violations tied to its Bloomington Drosophila Stock Center, which had exported genetically modified fruit flies engineered to produce a subunit of a controlled toxin to research institutions worldwide without the export licenses the EAR required. The settlement was non-monetary: Indiana University agreed to deliver EAR compliance training, present on the underlying conduct to stock-center directors and the broader university export-control community, and accepted a one-year suspended denial order. IU had voluntarily self-disclosed the conduct and cooperated with BIS’s Office of Export Enforcement, which is very likely why the resolution stopped short of a financial penalty.
The lesson generalizes well beyond fruit flies. Any core facility, biorepository, or shared-instrumentation lab that ships materials, strains, or equipment to external collaborators — domestic or foreign — is a potential EAR touchpoint if any of what it ships is separately controlled (in this case, because the genetic modification itself produced a listed toxin subunit). Routine shipping logistics, not classified research, is where most research-institution export exposure actually originates.
What actually triggers a violation, across both the 2026 industry cases and the IU precedent
- Reexport without reauthorization. Both Applied Materials and Indiana University involved items moving to a second destination or additional recipients beyond what the original license or exemption covered — not an initial export decision made in bad faith, but a failure to re-check authorization at the next transfer.
- Missed or informal classification. Determining whether an item, technology, or biological material has an Export Control Classification Number (ECCN) that restricts its destination is the step both cases show getting skipped or handled informally. See CASRAI’s ECCN lookup guide for how self-classification is supposed to work.
- Destination and end-user screening gaps. Whether the counterparty is on a restricted or denied-persons list, or in a comprehensively sanctioned or embargoed jurisdiction, is exactly the check both 2026 industry cases and the IU case turned on. CASRAI’s embargoed countries list covers the OFAC and BIS destination controls that apply to university research.
- No documented compliance program to point to. BIS’s own guidance and its settlement terms consistently reward institutions that can show a functioning compliance structure and self-disclose, as IU did, over those that cannot. CASRAI’s four pillars of export control compliance guide and EAR compliance checklist lay out what that structure needs to include.
What research offices should take from the 2026 numbers
The scale of the 2026 industry penalties is not a direct predictor of what a research institution would face for a comparable violation — BIS calibrates penalties to transaction value, and university shipments of research materials rarely approach semiconductor-equipment dollar figures. What does transfer directly is the enforcement logic: BIS is actively working reexport and destination-screening cases across sectors, self-disclosure and cooperation measurably change the outcome (as in the IU case), and the compliance infrastructure question — can the institution show classification, screening, and licensing were actually checked — is what determines whether an incident becomes a settlement with a suspended denial order or one with a payable penalty attached. Research offices with core facilities, biorepositories, international collaborations, or shared equipment loans are the parts of an institution most exposed to this fact pattern, and are the right places to prioritize a compliance review against CASRAI’s export control reform and research security guide and the broader integrity and compliance resources.
Frequently asked questions
Is the Applied Materials penalty really the largest BIS has ever imposed?
Trade-compliance counsel covering the settlement have described it as a record penalty and confirm it is the statutory maximum for the transactions involved, with several characterizing it as BIS’s second-largest civil penalty to date. BIS has not published a definitive all-time ranking, so this page describes it as a record-scale penalty rather than asserting an unqualified all-time-largest claim.
Does the Applied Materials case involve any university or research institution?
No. It is a commercial semiconductor-equipment reexport case. It is included here because it is the clearest evidence of BIS’s current enforcement intensity and legal theory (unauthorized reexport), which is the same theory applied in the university-specific Indiana University case discussed above.
Why does this page cite a 2024 case in a piece about 2026 enforcement trends?
Because BIS has not yet published a 2026 settlement involving a university or academic research center at the time of writing. The Indiana University case remains the most recent, clearly documented example of how BIS applies export-control enforcement inside a research institution, and its fact pattern — unlicensed shipment of a controlled biological item to research collaborators — is exactly the kind of exposure the 2026 industry cases suggest BIS continues to actively pursue.
What is the practical first step for a research office reviewing this?
Confirm that any core facility, biorepository, or equipment-sharing arrangement that ships materials externally has documented ECCN classification and destination/end-user screening in place, and that staff know how and when to escalate for a license determination. CASRAI’s EAR compliance checklist and ECCN lookup guide, linked above, are the starting points.
Sources: Bureau of Industry and Security, bis.gov/enforcement; BIS press release on the Indiana University settlement, bis.gov; law-firm summaries of the Applied Materials settlement from Arnold & Porter and ArentFox Schiff.
